We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
-7.96%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$1.02B
AUM Growth
-$942M
Cap. Flow
-$762M
Cap. Flow %
-74.8%
Top 10 Hldgs %
36.57%
Holding
87
New
6
Increased
6
Reduced
47
Closed
24

Top Buys

Rank Stock Value
1
TMDX icon
Transmedics
TMDX
+$15.3M
2
JANX icon
Janux Therapeutics
JANX
+$9.52M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$7.05M
4
DXCM icon
DexCom
DXCM
+$5.77M
5
RCKT icon
Rocket Pharmaceuticals
RCKT
+$4.58M

Top Sells

Rank Stock Value
1
NTRA icon
Natera
NTRA
+$48.4M
2
ISRG icon
Intuitive Surgical
ISRG
+$43.4M
3
BSX icon
Boston Scientific
BSX
+$39.3M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$29.6M
5
ILMN icon
Illumina
ILMN
+$26M

Sector Composition

Rank Sector Weight
1 Healthcare 98.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VERA icon
51
Vera Therapeutics
VERA
$2.39B
$4.23M 0.42%
+100,000
New +$4.43M
RGNX icon
52
Regenxbio
RGNX
$615M
$4.11M 0.4%
532,000
-600,564
-53% -$5.64M
QURE icon
53
uniQure
QURE
$2.52B
$3.92M 0.39%
222,000
-451,618
-67% -$3.9M
KZR
54
DELISTED
Kezar Life Sciences
KZR
$3.38M 0.33%
502,600
– –
KROS icon
55
Keros Therapeutics
KROS
$199M
$3.32M 0.33%
210,000
-83,200
-28% -$4.32M
AKRO
56
DELISTED
Akero Therapeutics
AKRO
$2.28M 0.22%
+82,000
New +$2.48M
DYN icon
57
Dyne Therapeutics
DYN
$4.28B
$2.26M 0.22%
96,000
-69,000
-42% -$2.04M
COGT icon
58
Cogent Biosciences
COGT
$6.95B
$2.24M 0.22%
287,104
-713,896
-71% -$7.11M
NMRA icon
59
CALL
Neumora Therapeutics
NMRA
$311M
$1.59M 0.16%
+150,000
New +$1.8M
SCYX icon
60
SCYNEXIS
SCYX
$36M
$1.49M 0.15%
153,614
-27,477
-15% -$285K
KPTI icon
61
Karyopharm Therapeutics
KPTI
$161M
$1.37M 0.13%
134,567
– –
HYPR icon
62
Hyperfine
HYPR
$90.9M
$1.05M 0.1%
1,188,178
– –
BLUE
63
DELISTED
bluebird bio
BLUE
$680K 0.07%
81,555
-2
-0% -$17
APGE icon
64
Apogee Therapeutics
APGE
$10.1B
– –
-154,000
Closed -$9.05M
ARGX icon
65
argenx
ARGX
$54.6B
– –
-38,200
Closed -$20.7M
BMRN icon
66
BioMarin Pharmaceuticals
BMRN
$12B
– –
-320,000
Closed -$22.5M
BNTX icon
67
BioNTech
BNTX
$23.4B
– –
-145,000
Closed -$17.2M
CGEM icon
68
Cullinan Oncology
CGEM
$1.07B
– –
-425,000
Closed -$7.11M
HELP
69
Cybin Inc
HELP
$471M
– –
-918,000
Closed -$8.16M
EDIT icon
70
Editas Medicine
EDIT
$402M
– –
-1,465,000
Closed -$5M
ESTA icon
71
Establishment Labs
ESTA
$2.7B
– –
-169,000
Closed -$7.31M
GPCR icon
72
Structure Therapeutics
GPCR
$3.4B
– –
-430,900
Closed -$18.9M
IMCR icon
73
Immunocore
IMCR
$1.7B
– –
-200,000
Closed -$6.23M
IMNM icon
74
Immunome
IMNM
$2.63B
– –
-873,891
Closed -$12.8M
IMVT icon
75
Immunovant
IMVT
$7.99B
– –
-99,000
Closed -$2.82M
1 2
3
4

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Avidity Partners Management's Q4 2024 Portfolio in Review

As of Q4 2024, Avidity Partners Management held 87 positions worth $1.02B, down 48% from $1.96B the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Avidity Partners Management withdrew a net $762M in Q4 2024, closing 24 positions and reducing 47 holdings. Its most notable exit was BioMarin Pharmaceuticals, an estimated $22.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier.

Against the trend, Avidity Partners Management opened a new position in Regeneron Pharmaceuticals worth $5.98M.

  • Avidity Partners Management's largest Q4 2024 buy was Regeneron Pharmaceuticals: 8,400 shares worth $5.98M.
  • Avidity Partners Management added most to Transmedics in Q4 2024, an estimated $15.3M increase.
  • Avidity Partners Management's biggest Q4 2024 reduction was Natera, cutting an estimated $48.4M.
  • Avidity Partners Management fully exited BioMarin Pharmaceuticals in Q4 2024, selling an estimated $22.5M.
  • Avidity Partners Management's ten largest holdings make up 37% of its $1.02B portfolio in Q4 2024.
  • Avidity Partners Management opened 6 new positions and closed 24 in Q4 2024.
  • Avidity Partners Management's portfolio value fell 48% quarter-over-quarter to $1.02B.

Based on Avidity Partners Management's 13F filing for Q4 2024, filed 14 Feb 2025.